Pharmaceutical News: Health Industry and corruption

In 2014, when Prime Minister Modi's government came into power, it issued new guidelines for the pharmaceutical industry. The government stressed the importance of implementing controls within the medical sector and advocated for self-regulation, suggesting that the industry should impose restrictions on itself to prevent the necessity of enforced regulatory measures. This was in line with the creation of self-regulatory bodies across various sectors, including the media, with the aim of enhancing governance and reducing corruption.

Further edits and discussions around these guidelines emphasized the need for the pharmaceutical industry to manage its own affairs more rigorously. However, it was questioned whether such self-regulation had been effectively implemented. The Modi government, after its inception in 2014, undertook significant reforms to reduce corruption, particularly in the medical field. Despite these efforts, the pharmaceutical industry in India remains vast and operates on a large scale, not only domestically but also internationally. This has led to widespread concern about the pervasive issues within the industry, especially regarding the availability and oversight of medical equipment.

Small-scale medical facilities across the country are equipped with essential diagnostic machines like X-rays, MRIs, and ultrasound machines, which are often sold without adequate regulatory checks. Many doctors using these machines are not sufficiently skilled, leading to a commercialization of healthcare where the emphasis seems to be more on financial gain than on patient care. This situation has sparked widespread debate and concern about the effectiveness of self-regulation and the ethical implications of commercial pressures in healthcare.